NCT04985955View on ClinicalTrials.gov

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

September 21, 2021

Study Completion Date

September 21, 2021

Conditions
Healthy
Interventions
DRUG

Tofacitinib

Tofacitinib tablet will be administered orally.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04985955 - A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3 | Biotech Hunter | Biotech Hunter